Setup

SpyGlass Pharma (SGP) IPO'd February 2026 at $16, with sell-side mean target $45 (5 Buys, 0 Holds, 0 Sells). Lead product BIM-IOL — a bimatoprost-eluting intraocular lens placed during cataract surgery for glaucoma — has Phase 3 trials enrolling, NDA targeted for 2028. The Q1 2026 10-Q disclosed an active Glaukos trade secret lawsuit in boilerplate language. Public court records say something more specific.

What the filings say

SGP's Q1 10-Q describes Glaukos Corporation v. Doan / SpyGlass Pharma (Case 8:25-cv-02105, C.D. Cal., filed September 17, 2025) as an "ongoing matter" SGP "vehemently denies," with no loss accrual.

GKOS's FY2025 10-K, filed February 23, 2026, discloses the same case in approximately 30 lines:

• Preliminary injunction granted December 11, 2025. The federal court found GKOS "likely to prevail on merits, at risk of irreparable harm" — a pre-trial merits ruling on the trade secret claim.
• Named individual defendant: Long Doan, now VP Clinical Research at SGP, previously eight years at Glaukos where his public profile credits him with leading "clinical and operational oversight of the iDose platform" (LinkedIn, ZoomInfo, SpyGlass About page).
• 13,000+ documents allegedly uploaded by Doan to a personal Google Drive before resignation.
• Amended complaint filed March 2026 (escalation, not retreat).
• Trial scheduled October 27, 2026 — preceding Phase 3 completion (2027) and NDA submission (2028).
• GKOS seeks treble damages and permanent injunction in addition to compensatory relief.

SGP's Q1 2026 G&A jumped 401% year-over-year ($1.4M → $6.9M), including $3.7M in legal and professional services — consistent with active defense spend.

What the market thinks

Five sell-side firms (HC Wainwright, Citi, Leerink, Jefferies, Stifel) initiated coverage in March 2026 with Buy ratings and price targets between $37 and $62 (mean $45, +94% upside from IPO price). Published initiation notes treat the lawsuit as boilerplate IP risk. None reference the December 2025 preliminary injunction grant.

Stock sits below its 50DMA and 200DMA, within 15% of its 52-week low. Short interest 8.0% of float, 11.8 days to cover — meaningful for a recent IPO. No listed options, so market-implied probabilities cannot be extracted directly.

Implied scenario weighting from analyst consensus: Phase 3 succeeds with clean litigation ≈65%, muddle through ≈20%, adverse outcomes ≈15%. The lawsuit is modeled as generic biotech IP-litigation risk, not a court-validated event.

Why the gap exists

PACER entries for Case 8:25-cv-02105 are public but not aggregated. The PI grant appears in GKOS's 10-K Item 3. The named defendant's identity is on LinkedIn and ZoomInfo. The document count is on the docket. Each piece is public; the synthesis is not. SGP's own Q1 10-Q omits the PI grant, the trial date, and Doan's identity entirely.

The five covering firms initiated within days of IPO and built valuation models on an iDose-style revenue trajectory ($136M iDose TR in 18 months validates the pricing path). Litigation appears as a generic disclosure line, not a probability-weighted scenario. No firm has updated coverage to reflect the December 2025 preliminary injunction.

A common settlement pattern in our notes — claimant gives one sentence in a generic risk factor while the target runs a full risk factor — typically points to negotiated resolution. That pattern is INVERTED here: PI granted, amended complaint, trial date set, permanent injunction sought. GKOS's earnings-call silence on the lawsuit is most likely court-ordered protective-order silence, not strategic hedging.

Risks (ranked by impact)

1. Settlement with margin haircut. Modal outcome. Trade secret cases with PI grants and mechanically differentiated products (drug-eluting IOL vs intracameral implant) often resolve via royalty or license rather than product injunction. Combined "clean settlement" + "settlement with material royalty" estimated ≈55% probability.
2. Phase 3 readout (2028) succeeds. Phase 1/2 data (37% IOP reduction, 95% off drops at 36 months) is independent of disputed information. Strong if enrollment holds; SGP has been opaque on enrollment counts in SEC filings.
3. Permanent injunction limiting BIM-IOL. Tail risk estimated ≈8%. Catastrophic state — court has already granted preliminary relief and Doan brought knowledge from the iDose program — but mechanical product differentiation argues against product-killing relief.
4. Material weakness in internal controls (third consecutive year). CFO three months in seat. Governance overhang caps the institutional buyer base. Q1 10-Q explicitly states disclosure controls were not effective as of March 31, 2026.

Catalysts

• Q2 2026 10-Q (~mid-August) — does it reference the December 2025 preliminary injunction or the October 2026 trial date? Q1 omitted both.
• Lock-up expiry, August 2026 — approximately 22.6 million shares (67.8% of float) become eligible for sale.
• Trial October 27, 2026 — or settlement before.
• Phase 3 enrollment milestone announcements — unscheduled, most likely via press release or conference.
• GKOS earnings calls (Q2 ~early August, Q3 ~early November) — watch for any narrative mention of SpyGlass in MD&A. Silence is currently court-ordered.

What would change our mind

• 8-K settlement announcement with clean terms (no royalty, no equity, no operational restriction) → litigation factor resolves.
• SGP files 8-K amending Q1 10-Q to include the preliminary injunction → counsel-forced disclosure confirms severity.
• Phase 3 enrollment ≥50% complete by year-end 2026 → science accelerates ahead of trial; thesis balance shifts.
• Pre-trial summary judgment for SGP → would require adverse PI ruling to be functionally revisited.
• Joint stipulation or court mediation referral → settlement signal even before terms surface.

Evidence